Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Dow Jones03-27

By Denny Jacob

Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.

The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research.

Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter.

Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial.

Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer.

Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sciences.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

March 27, 2025 07:56 ET (11:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522374757?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-27 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522374757","market":"hk","top_or_hot":-1,"title":"Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research. \n</p>\n<p>\n  Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter. \n</p>\n<p>\n  Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial. \n</p>\n<p>\n  Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer. \n</p>\n<p>\n  Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sciences. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2025 07:56 ET (11:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-27 19:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research. \n</p>\n<p>\n  Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter. \n</p>\n<p>\n  Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial. \n</p>\n<p>\n  Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer. \n</p>\n<p>\n  Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sciences. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2025 07:56 ET (11:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522374757","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522374757","pubTimestamp":1743076560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research.Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter.Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial.Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer.Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","ABUS":"Arbutus Biopharma Corporation","ROIV":"Roivant Sciences Ltd."},"translate_title":"Arbutus Biopharma裁员一半以上，在高管洗牌中聘请新首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1,"ROIV":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency. \n\n\n  The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research. \n\n\n  Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter. \n\n\n  Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial. \n\n\n  Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer. \n\n\n  Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sciences. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 07:56 ET (11:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522374757"}